U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 001-40715 PetVivo Holdings, Inc. (Name of small business issuer in its charter) (State or other jurisdiction of incorporation or organ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40715 PetVivo Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0363559 (State or other ...

Financial Data and Key Metrics Changes - For the nine months ended December 31, 2022, the company reported revenues of $792,000 compared to $60,000 in the prior year period, driven by $575,000 from shipments of Spryng to MWI [2] - For the third quarter of fiscal 2023, revenues were $510,000 compared to $51,000 in the same quarter of fiscal 2022, with $457,000 from shipments of Spryng to MWI [80][81] - As of December 31, 2022, the company had $375,000 in cash and working capital of $171,000 [2] Business Line Data and Key Metrics Changes - The significant revenue increase is attributed to the exclusive distribution partnership with MWI Animal Health, which began in June 2022 [80] - The company plans to move all production to a new facility starting August 2023, which will enhance manufacturing capacity [82] Market Data and Key Metrics Changes - The market for osteoarthritis (OA) and lameness treatment in the United States is estimated to exceed $4.8 billion annually [102] - The company is seeing good adoption rates among veterinary doctors, with positive feedback from initial product trials [77] Company Strategy and Development Direction - The company aims to generate clinical evidence to support the equine and small animal markets, with several studies expected to conclude and be published in fiscal 2023 [83] - The focus is on expanding sales and marketing efforts, clinical studies, and manufacturing capacity to increase vet acceptance and sales of Spryng [82][95] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the relationship with MWI and the positive reception of Spryng at veterinary conferences, indicating a growing awareness and acceptance of the product [90][84] - The company anticipates that clinical study results will begin to be publicly disclosed in March 2023, which is expected to further support sales efforts [97] Other Important Information - The company raised approximately $1.4 million in January 2023 through a direct offering, which will support ongoing operations and expansion [92] - The company is working with renowned research organizations for clinical trials, enhancing credibility and potential market penetration [108] Q&A Session Summary Question: What is the size of the markets in terms of the number of animals? - The U.S. has approximately 64 million dogs, 53 million cats, and 8 to 14 million horses, with the majority of current revenues coming from the equine market due to more frequent veterinary visits [110] Question: What is the burn rate and upcoming milestones? - The burn rate is around $2 million per quarter, with multiple clinical studies expected to yield results that will aid in product adoption [37] Question: What prompted the expansion into another facility? - The new facility will allow for greater efficiency and scalability, supporting future growth without disrupting current production [124]

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 001-40715 PetVivo Holdings, Inc. (Name of small business issuer in its charter) Nevada 99-0363559 (State or other jurisdiction of incorporation or organization) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterl ...

PetVivo Holdings, Inc. (OTCPK:PETV) Q2 2023 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants John Dolan – Chief Business Development Officer and General Counsel John Lai – President and Chief Executive Officer Bob Folkes – Chief Financial Officer Conference Call Participants John Dolan All right. Let us begin the conference. Greetings and welcome to the PetVivo Holdings Second Quarter Fiscal Year 2023 Financial Results Conference Call. I am John Dolan, the Chief Business Developmen ...

PetVivo Holdings, Inc. (OTCPK:PETV) Q1 2023 Results Conference Call August 11, 2022 5:00 PM ET Company Participants John Lai - Chief Executive Officer and President John Dolan - Chief Business Development Officer and General Counsel Robert Folkes - Chief Financial Officer Conference Call Participants Gary Zwetchkenbaum - Plum Tree Consulting LLC John Dolan Greetings, everyone. And welcome to the PetVivo Holdings First Quarter of Fiscal 2023 Financial Results Conference Call. I am John Dolan, the Chief Busin ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company reported a net loss of $1.97 million and decreased assets, raising substantial doubt about its going concern status [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $5.72 million due to a decline in cash, while stockholders' equity fell to $4.25 million Condensed Consolidated Balance Sheet Highlights (Unaudited) | Account | June 30, 2022 | March 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $4,378,668 | $6,106,827 | | Total Current Assets | $5,069,038 | $6,755,400 | | **Total Assets** | **$5,723,557** | **$7,427,332** | | Total Current Liabilities | $1,220,632 | $1,173,486 | | **Total Liabilities** | **$1,471,032** | **$1,440,610** | | **Total Stockholders' Equity** | **$4,252,525** | **$5,986,722** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Revenue grew to $58,174 post-product launch, but surging operating expenses drove a net loss of $1.97 million Statement of Operations Summary (Unaudited) | Metric | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | | :--- | :--- | :--- | | Revenues | $58,174 | $4,145 | | Gross Profit (Loss) | $5,154 | ($906) | | Total Operating Expenses | $1,971,247 | $517,613 | | Operating Loss | ($1,966,093) | ($518,519) | | **Net Loss** | **($1,965,428)** | **($490,629)** | | **Net Loss Per Share** | **($0.20)** | **($0.07)** | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations increased significantly to $1.70 million, reducing the company's quarter-end cash balance to $4.38 million Cash Flow Summary (Unaudited) | Activity | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | | :--- | :--- | :--- | | Net Cash Used In Operating Activities | ($1,701,699) | ($255,861) | | Net Cash Used in Investing Activities | ($24,897) | ($6,063) | | Net Cash (Used in) Provided by Financing Activities | ($1,563) | $381,430 | | **Net (Decrease) Increase in Cash** | **($1,728,159)** | **$119,506** | | **Cash at End of Period** | **$4,378,668** | **$143,084** | [Notes to Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes disclose a going concern warning due to a $65.1 million accumulated deficit, details on stock compensation, and a legal dispute - The company is in the business of licensing and commercializing medical devices and biomaterials for animals, with its headquarters in Minneapolis, Minnesota[24](index=24&type=chunk) - The company incurred a net loss of **$1,965,428** for the quarter and has an accumulated deficit of **$65,091,849** as of June 30, 2022, raising substantial doubt about its ability to continue as a **going concern**[79](index=79&type=chunk) - Total stock-based compensation expense for the three months ended June 30, 2022, was **$231,231**, a significant increase from $55,674 in the same period of 2021[98](index=98&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses revenue growth from its Spryng™ product, rising expenses, and a going concern risk with a seven-month cash runway - The company is an emerging biomedical device company focused on commercializing innovative medical devices for animals, with its lead product being Spryng™ for managing lameness and osteoarthritis in dogs and horses[99](index=99&type=chunk) - On June 17, 2022, the company entered into an exclusive two-year distribution agreement with **MWI Veterinary Supply Co.** to market and sell Spryng™ in the United States[112](index=112&type=chunk) - The company's working capital was **$3,848,406** at June 30, 2022, which management believes is sufficient to fund operations for the next **seven months** but will require additional capital thereafter[126](index=126&type=chunk)[135](index=135&type=chunk) [Results of Operations](index=20&type=section&id=Results%20of%20Operations) Revenue grew to $58,174 from the Spryng™ launch, but higher sales, marketing, and G&A costs widened the net loss to $1.97 million Quarterly Operational Results Comparison | Metric | Q2 2022 | Q2 2021 | | :--- | :--- | :--- | | Revenues | $58,174 | $4,145 | | Sales and Marketing Expenses | $656,569 | $49,731 | | General and Administrative Expenses | $1,243,022 | $330,945 | | Research and Development Expenses | $71,656 | $136,937 | | **Net Loss** | **($1,965,428)** | **($490,629)** | - The increase in net loss was primarily driven by costs to support the launch of Spryng™ and incremental public company costs incurred in the quarter[124](index=124&type=chunk) [Liquidity and Capital Resources](index=22&type=section&id=Liquidity%20and%20Capital%20Resources) The company holds $4.38 million in cash and $3.85 million in working capital, sufficient for seven months before requiring new financing - The company closed an underwritten public offering on August 13, 2021, with net proceeds of approximately **$9,781,000**[125](index=125&type=chunk) - As of June 30, 2022, the company had **$4,378,668 in cash** and cash equivalents and **working capital of $3,848,406**[126](index=126&type=chunk) - The company will need to **raise additional capital** in the future to support its efforts to commercialize Spryng™ and fund ongoing operations[127](index=127&type=chunk) [Qualitative and Quantitative Disclosures About Market Risk](index=24&type=section&id=Item%203.%20Qualitative%20and%20Quantitative%20Disclosures%20About%20Market%20Risk) The company is exempt from providing market risk disclosures as it qualifies as a "smaller reporting company" - As a **"smaller reporting company,"** the company is exempt from providing disclosures about market risk[142](index=142&type=chunk) [Controls and Procedures](index=24&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were not effective as of the end of the reporting period - Management concluded that the company's disclosure controls and procedures were **not effective** as of the end of the reporting period[144](index=144&type=chunk) - **No significant changes** were made to internal controls over financial reporting during the first quarter of fiscal year 2023[145](index=145&type=chunk) [PART II. OTHER INFORMATION](index=25&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=25&type=section&id=Item%201.%20Legal%20Proceedings) The company is in a legal dispute with its former CTO over an alleged breach of contract, which it believes is without merit - The company has received correspondence from an attorney for Dr. David Masters, former CTO, alleging breach of a settlement and consulting agreement[76](index=76&type=chunk) - The company believes the claims are **without merit** and does not anticipate a material impact on its financial position or results of operations[76](index=76&type=chunk)[147](index=147&type=chunk) [Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) This report refers investors to the risk factors previously disclosed in the company's Annual Report on Form 10-K - The report refers to the risk factors discussed in the company's **2022 10-K Report**, stating they could materially affect the business[149](index=149&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=25&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered equity was sold, and the use of proceeds from the August 2021 public offering remains materially unchanged - There were **no unregistered sales** of equity securities in the quarter[150](index=150&type=chunk) - The company completed a Public Offering on August 13, 2021, raising net proceeds of approximately **$9,781,000**[152](index=152&type=chunk) - A portion of the proceeds was used for debt repayment of **$101,400**, with no material change in the intended use of remaining proceeds[153](index=153&type=chunk)[154](index=154&type=chunk) [Exhibits](index=27&type=section&id=Item%206.%20Exhibits) This section lists filed exhibits, including a new distribution agreement with MWI Veterinary Supply Co and officer certifications - A **Distribution Services Agreement** dated June 17, 2022, between the company and MWI Veterinary Supply Co, Inc was filed as an exhibit[160](index=160&type=chunk) - Certifications from the Principal Executive Officer and Principal Financial Officer pursuant to **Sarbanes-Oxley Sections 302 and 906** were also filed[160](index=160&type=chunk)

PetVivo Holdings, Inc. (OTCPK:PETV) Q4 2022 Earnings Conference Call June 29, 2022 5:00 PM ET Company Participants John Lai - Chief Executive Officer and President John Dolan - Chief Business Development Officer and General Counsel Robert Folkes - Chief Financial Officer Conference Call Participants Gary Zwetchkenbaum - Plum Tree Consulting LLC John Lai John Dolan, can you start the introductions? John Dolan Yes. Thank you, John. Greetings, and welcome to the PetVivo Holdings Fiscal Year Ended March 31, 202 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 000-55167 PetVivo Holdings, Inc. Securities registered under Section 12(g) of the Act: (Exact name of registrant as speci ...

PetVivo Holdings, Inc. (OTCPK:PETV) Q3 2022 Earnings Conference Call February 10, 2022 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - Chief Executive Officer and President Robert Folkes - Chief Financial Officer Conference Call Participants Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corres ...